Ajanta Pharma announced the re-appointment of its Internal Auditors, Cost Auditors, and Tax Auditors for the financial year 2026-27, following approvals at the Board meeting held on Tuesday, May 5, 2026. The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.

Key Audit Appointments for FY 2026-27

The Board approved the re-appointment of three professional firms across distinct audit functions. The following table summarises the key details of each appointment:

The re-appointment of M/s. RA & Co. as Cost Auditors is subject to ratification of their remuneration by the members of the Company, in accordance with the provisions of Section 148 of the Companies Act, 2013 and rules made thereunder.

Profiles of Re-appointed Audit Firms

Internal Auditors: M/s. Aneja Assurance Pvt. Ltd.

Aneja Assurance Pvt. Ltd. is a Mumbai-based internal audit and risk advisory firm with over 40 years of experience. The firm specialises in internal audits, risk management, governance, and compliance services across sectors such as pharmaceuticals, BFSI, and manufacturing. The firm is staffed by professionals including CAs, CIAs, and MBAs, and leverages advanced tools to deliver assurance services aligned with global standards.

Cost Auditors: M/s. RA & Co.

M/s. RA & Co., Cost Accountants, is a Cost & Management Consultancy firm that has been rendering professional services across India for the last three decades. The firm's partners bring extensive experience in the field of cost accounting and management consultancy.

Tax Auditors: M/s. R S Sanghai & Associates

M/s. R S Sanghai & Associates, Chartered Accountants, holds in-depth expertise in direct and indirect tax laws. The firm is recognised for quality deliverables delivered in an efficient and timely manner, and is known for providing solutions across complex tax matters.

Regulatory Compliance

The re-appointments and associated disclosures were communicated to BSE Limited and the National Stock Exchange of India in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Gaurang Shah, Sr. VP – Legal & Company Secretary of Ajanta Pharma, on May 5, 2026.

Ajanta Pharma disclosed on May 5, 2026, that its Nomination and Remuneration Committee of the Board of Directors convened a meeting and approved key decisions relating to its Employee Stock Option Plan (ESOP). The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ESOP Grant Details

The committee approved the grant of stock options under the Ajanta Pharma Share Based Incentive Plan 2019. The key parameters of the grant are outlined below:

Cancellation of Stock Options

In addition to the fresh grant, the Nomination and Remuneration Committee also approved the cancellation of 850 stock options. These cancelled options have been credited back to the ESOP pool, making them available for future grants under the plan.

Regulatory Disclosure

The intimation was submitted to both BSE Limited and the National Stock Exchange of India in compliance with applicable SEBI listing regulations. The communication was signed by Gaurang Shah, Sr. VP - Legal & Company Secretary, on May 5, 2026.